Literature DB >> 16670756

T cell control in autoimmune bullous skin disorders.

Michael Hertl1, Rüdiger Eming, Christian Veldman.   

Abstract

Autoimmune bullous disorders are a group of severe skin diseases characterized clinically by blisters and erosions of skin and/or mucous membranes. A hallmark of these disorders is the presence of IgG and occasionally IgA autoantibodies that target distinct adhesion structures of the epidermis, dermoepidermal basement membrane, and anchoring fibrils of the dermis. This Review focuses on the potential role of autoreactive T cells in the pathogenesis of these disorders. Pemphigus vulgaris (PV) and bullous pemphigoid (BP) are the best-characterized bullous disorders with regard to pathogenesis and T cell involvement. Activation of autoreactive T cells in PV and BP is restricted by distinct HLA class II alleles that are prevalent in individuals with these disorders. Autoreactive T cells are not only present in patients but can also be detected in healthy individuals. Recently, a subset of autoreactive T cells with remarkable regulatory function was identified in healthy individuals and to a much lesser extent in patients with PV, suggesting that the occurrence of autoimmune bullous disorders may be linked to a dysfunction of Tregs.

Entities:  

Mesh:

Year:  2006        PMID: 16670756      PMCID: PMC1451217          DOI: 10.1172/JCI28547

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain.

Authors:  M S Lin; C L Fu; G J Giudice; M Olague-Marchan; A M Lazaro; P Stastny; L A Diaz
Journal:  J Invest Dermatol       Date:  2000-12       Impact factor: 8.551

2.  Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations.

Authors:  K B Yancey; C A Egan
Journal:  JAMA       Date:  2000-07-19       Impact factor: 56.272

3.  Desmoglein-1-specific T lymphocytes from patients with endemic pemphigus foliaceus (fogo selvagem).

Authors:  M S Lin; C L Fu; V Aoki; G Hans-Filho; E A Rivitti; J R Moraes; M E Moraes; A M Lazaro; G J Giudice; P Stastny; L A Diaz
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

4.  Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production.

Authors:  K Nishifuji; M Amagai; M Kuwana; T Iwasaki; T Nishikawa
Journal:  J Invest Dermatol       Date:  2000-01       Impact factor: 8.551

Review 5.  Humoral and cellular autoimmunity in autoimmune bullous skin disorders.

Authors:  M Hertl
Journal:  Int Arch Allergy Immunol       Date:  2000-06       Impact factor: 2.749

6.  IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris.

Authors:  S Spaeth; R Riechers; L Borradori; D Zillikens; L Büdinger; M Hertl
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

7.  Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production.

Authors:  J Setterfield; J Theron; R W Vaughan; K I Welsh; E Mallon; F Wojnarowska; S J Challacombe; M M Black
Journal:  Br J Dermatol       Date:  2001-09       Impact factor: 9.302

8.  Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay.

Authors:  R Eming; L Büdinger; R Riechers; O Christensen; H Bohlen; R Kalish; M Hertl
Journal:  Br J Dermatol       Date:  2000-12       Impact factor: 9.302

9.  Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls.

Authors:  L Büdinger; L Borradori; C Yee; R Eming; S Ferencik; H Grosse-Wilde; H F Merk; K Yancey; M Hertl
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

10.  Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus.

Authors:  M Amagai; K Tsunoda; H Suzuki; K Nishifuji; S Koyasu; T Nishikawa
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

View more
  41 in total

Review 1.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

Review 2.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Nothing but skin and bone.

Authors:  F Patrick Ross; Angela M Christiano
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion.

Authors:  David Rafei; Ralf Müller; Norito Ishii; Maria Llamazares; Takashi Hashimoto; Michael Hertl; Rüdiger Eming
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 5.  [Involvement of mucous membranes in autoimmune bullous diseases].

Authors:  C Günther
Journal:  Hautarzt       Date:  2016-10       Impact factor: 0.751

6.  Antibodies to the desmoglein 1 precursor proprotein but not to the mature cell surface protein cloned from individuals without pemphigus.

Authors:  Jun Yamagami; Stephen Kacir; Ken Ishii; Aimee S Payne; Don L Siegel; John R Stanley
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

7.  Refractory pemphigus foliaceous treated with rituximab.

Authors:  Fatima Awdeh; Eimear Gilhooley; Ciara O Grady; Maureen Connolly
Journal:  BMJ Case Rep       Date:  2019-05-29

8.  Enrichment of total serum IgG4 in patients with pemphigus.

Authors:  T Funakoshi; L Lunardon; C T Ellebrecht; A R Nagler; C E O'Leary; A S Payne
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

Review 9.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

Review 10.  A perspective of pemphigus from bedside and laboratory-bench.

Authors:  Yasuo Kitajima; Yumi Aoyama
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.